ATE179185T1 - Verbundmaterial mit kleinem durchmesser, welches ein wasserlösliches carboxylpolysaccharid und magnetisches eisenoxid enthaltet - Google Patents

Verbundmaterial mit kleinem durchmesser, welches ein wasserlösliches carboxylpolysaccharid und magnetisches eisenoxid enthaltet

Info

Publication number
ATE179185T1
ATE179185T1 AT94906771T AT94906771T ATE179185T1 AT E179185 T1 ATE179185 T1 AT E179185T1 AT 94906771 T AT94906771 T AT 94906771T AT 94906771 T AT94906771 T AT 94906771T AT E179185 T1 ATE179185 T1 AT E179185T1
Authority
AT
Austria
Prior art keywords
iron oxide
magnetic iron
carboxylpolysaccharide
composite material
water soluble
Prior art date
Application number
AT94906771T
Other languages
English (en)
Inventor
Masakatsu Doutokushin Hasegawa
Yoshio - Yamahana-Cho Ito
Hisato Tendo Shigo-Cho Yamada
Hideo - Higashino-Cho -C Nagae
Nahoko - Higashiyama-Ch Tozawa
Yukari Taishi -Chome Hino
Kyoji Bentengaoka Kito
Shusaburo Wakabadai - Hokukoku
Rudiger Lawaczeck
Wolfgang Ebert
Detlef Pfefferer
Susanne Wagner
Mayk Kresse
Original Assignee
Meito Sangyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16866463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE179185(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meito Sangyo Kk filed Critical Meito Sangyo Kk
Application granted granted Critical
Publication of ATE179185T1 publication Critical patent/ATE179185T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Hard Magnetic Materials (AREA)
  • Soft Magnetic Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Iron (AREA)
AT94906771T 1992-08-05 1993-08-04 Verbundmaterial mit kleinem durchmesser, welches ein wasserlösliches carboxylpolysaccharid und magnetisches eisenoxid enthaltet ATE179185T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22779292 1992-08-05

Publications (1)

Publication Number Publication Date
ATE179185T1 true ATE179185T1 (de) 1999-05-15

Family

ID=16866463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94906771T ATE179185T1 (de) 1992-08-05 1993-08-04 Verbundmaterial mit kleinem durchmesser, welches ein wasserlösliches carboxylpolysaccharid und magnetisches eisenoxid enthaltet

Country Status (9)

Country Link
US (1) US5766572A (de)
EP (1) EP0656368B2 (de)
JP (1) JP3337075B2 (de)
AT (1) ATE179185T1 (de)
DE (1) DE69324591T3 (de)
DK (1) DK0656368T4 (de)
ES (1) ES2130406T5 (de)
GR (1) GR3030030T3 (de)
WO (1) WO1994003501A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3337075B2 (ja) † 1992-08-05 2002-10-21 名糖産業株式会社 小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体
DE69332120T2 (de) * 1993-08-12 2003-02-27 Advanced Magnetics, Inc. Verwendung von mit polysacchariden überzogenen superparamagnetischen oxid-kolloiden
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
EP0783325B2 (de) * 1994-09-27 2004-03-31 Amersham Health AS Kontrastmittel
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
EP0877630B1 (de) 1996-01-10 2005-03-23 Amersham Health AS Kontrastmittel
DE59706019D1 (de) * 1996-08-05 2002-02-21 Schering Ag Vorrichtung und verfahren zur abtrennung magnetischer materialien aus pharmazeutischen zubereitungen, deren ausgangs- oder zwischenprodukten sowie mit hilfe dieser vorrichtung hergestellte mittel
EP0928809B1 (de) * 1996-08-30 2003-10-22 Meito Sangyo Kabushiki Kaisha Zusammensetzung enthaltend einen polysaccharidderivat und magnetisches eisenoxid
EP0967227A1 (de) * 1998-06-04 1999-12-29 Mitsubishi Gas Chemical Company, Inc. Verfahren zur Herstellung von Carboxypolysaccharid
US6203778B1 (en) 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
WO2001067105A1 (en) * 2000-03-06 2001-09-13 Dade Behring Marburg Gmbh Carriers coated with polysaccharides, their preparation and use
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
KR20020018260A (ko) * 2000-09-01 2002-03-08 조옥순 자동차 제동장치용 로터의 재질개선 방법
DE10046514A1 (de) * 2000-09-15 2002-04-25 Diagnostikforschung Inst Verfahren zur bildlichen Darstellung und Diagnose von Thromben mittels Kernspintomographie unter Verwendung partikulärer Kontrastmittel
GB0025414D0 (en) * 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
EP1335003A3 (de) * 2002-02-06 2004-04-07 Toyo Boseki Kabushiki Kaisha Magnetischer Träger der in der Lage ist Proteine zu binden und Verfahren zur Reinigung von Proteinen den magnetischen Träger verwendend
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
JP5230865B2 (ja) * 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
EP1810688A1 (de) * 2004-11-10 2007-07-25 Konica Minolta Medical & Graphic, Inc. Pharmazeutische zubereitung mit beschichteten magnetischen teilchen und verfahren zu ihrer herstellung und diagnose- und therapiesystem
EA012810B1 (ru) 2005-02-25 2009-12-30 Тетралоджик Фармасеутикалс Димерные ингибиторы ингибиторов белков апоптоза (iap)
JP5321772B2 (ja) * 2005-06-15 2013-10-23 戸田工業株式会社 磁性粒子含有医薬用原薬
EP1738773A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CA2617642A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20070258907A1 (en) * 2006-04-24 2007-11-08 Davis Mark E Polymer-coated paramagnetic particles
FR2918868A1 (fr) 2006-06-06 2009-01-23 Guerbet Sa Methode d'imagerie de diagnostic utilisant en combinaison avec l'imagerie de diffusion de l'eau, des agents de contraste
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009000824A (es) * 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
DE102007004424A1 (de) 2007-01-23 2008-07-24 Bayer Schering Pharma Aktiengesellschaft Eisenoxid-bindende Peptide
CN101547706B (zh) 2007-04-12 2013-07-10 延世大学校产学协力团 包含含锌磁性金属氧化物纳米颗粒的磁共振成像造影剂
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
JP2013526616A (ja) 2010-05-26 2013-06-24 ザ ジェネラル ホスピタル コーポレイション 磁性ナノ粒子
WO2012026194A1 (ja) * 2010-08-25 2012-03-01 国立大学法人 徳島大学 金属酸化物ナノ粒子構造体およびその製造方法
KR101303567B1 (ko) * 2011-03-08 2013-09-23 주식회사 인트론바이오테크놀로지 카르복실기가 도입된 만난으로 코팅된 자기공명영상 조영제 및 그것의 제조 방법
EP2679247B1 (de) * 2011-03-08 2018-09-19 Intron Biotechnology, Inc. Mit carbonsäuremannan beschichtetes kontrastmittel für die magnetresonanzbildgebung
JP6821665B2 (ja) 2015-06-04 2021-01-27 エンドマグネティクス リミテッド 磁気マーカ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4335094A (en) * 1979-01-26 1982-06-15 Mosbach Klaus H Magnetic polymer particles
US4370476A (en) † 1979-07-17 1983-01-25 Usher Thomas C Dextran polycarboxylic acids, ferric hydroxide complexes
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
SE463651B (sv) * 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
US4788281A (en) † 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
AU6621586A (en) * 1985-11-18 1987-06-02 University Of Texas System, The Polychelating agents for image and spectral enhancement (and spectral shift)
US4770183A (en) † 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4951675A (en) † 1986-07-03 1990-08-28 Advanced Magnetics, Incorporated Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
JP2726520B2 (ja) † 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH03141119A (ja) * 1989-10-25 1991-06-17 Nippon Telegr & Teleph Corp <Ntt> 磁性微粒子の製造方法
JP2558908B2 (ja) * 1990-02-16 1996-11-27 日本電信電話株式会社 磁性微粒子の製造方法
WO1992022586A1 (fr) † 1991-06-11 1992-12-23 Meito Sangyo Kabushiki Kaisha Composite oxyde comprenant du carboxypolysaccharide hydrosoluble et de l'oxyde de fer magnetique
JP3337075B2 (ja) † 1992-08-05 2002-10-21 名糖産業株式会社 小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体

Also Published As

Publication number Publication date
ES2130406T5 (es) 2003-12-16
DE69324591T2 (de) 1999-08-19
US5766572A (en) 1998-06-16
GR3030030T3 (en) 1999-07-30
DK0656368T4 (da) 2003-09-29
WO1994003501A1 (fr) 1994-02-17
EP0656368B1 (de) 1999-04-21
ES2130406T3 (es) 1999-07-01
DE69324591D1 (de) 1999-05-27
EP0656368A4 (de) 1996-05-08
DK0656368T3 (da) 1999-10-25
DE69324591T3 (de) 2004-02-12
EP0656368A1 (de) 1995-06-07
EP0656368B2 (de) 2003-06-04
JP3337075B2 (ja) 2002-10-21

Similar Documents

Publication Publication Date Title
DE69324591D1 (de) Verbundmaterial mit kleinem durchmesser, welches ein wasserlösliches carboxylpolysaccharid und magnetisches eisenoxid enthaltet
AU652060C (en) Oxidized composite comprising water-soluble carboxypolysaccharide and magnetic iron oxide
EP0275285A4 (de) Biodegradierbares superparamagnetisches material zur verwendung in klinischen anwendungen.
Renshaw et al. Immunospecific NMR contrast agents
PT683665E (pt) Composicao que responde magneticamente para transportar substancias biologicamente activas e metodos para a sua producao e utilizacao
KR930700161A (ko) 진단 작용제(Diagnostic Agents)
US5496534A (en) Squid magnetometry using ferri-and ferromagnetic particles
Haik et al. Biomagnetic fluid dynamics
Bulte et al. Magnetoliposomes as contrast agents
DE3872741T (de)
GR3027779T3 (en) Preparation for improving the blood supply containing hard magnetic particles
ATE99544T1 (de) Liposomale radiologische kontrastmittel.
Tsyb et al. Magnetic fluids at contrast media
Kirpotin et al. Magnetic targeting of a therapeutic antibody using magnetotropic microspheres of the interpolyelectrolyte coacervation complex
袁春波 et al. Effects of metal ions on the conformation of polar headgroup of sphingomyelin bilayer
Kushchevskaya Ferromagnetic particles use in medicine purposes
Milich et al. Effect of microfields of magnetically aligned media on Treponema pallidum. 1
Danilov et al. Concentration of erythrocyte-based magnetic carriers in the vascular bed
Wu et al. The Principle Properties and Application of Stainless Steel Magnetic Powder
Liang et al. Mossbauer study of(Sm sub 1 sub- sub x Nd sub x) sub 2 Fe sub 1 sub 7 and(Sm sub 1 sub- sub x Nd sub x) sub 2 Fe sub 1 sub 7 N sub y compounds
RU93054003A (ru) Многочувствительные частицы, способ их получения, способ диагностики
SG140993G (en) Use of ferromagnetic particles in contrast agents for NMR imaging and contrast agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0656368

Country of ref document: EP